
Annual report 2025
added 03-18-2026
ReWalk Robotics Ltd. Revenue 2011-2026 | RWLK
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ReWalk Robotics Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 M | 25.7 M | 13.9 M | 5.51 M | 5.97 M | 4.39 M | 4.87 M | 6.54 M | 7.75 M | 5.87 M | 3.75 M | 3.95 M | 1.59 M | 972 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.7 M | 972 K | 8.05 M |
Quarterly Revenue ReWalk Robotics Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.2 M | 5.72 M | 5.03 M | - | 6.13 M | 6.71 M | 5.28 M | - | 4.4 M | 1.34 M | 1.23 M | - | 886 K | 1.57 M | 876 K | - | 1.97 M | 1.44 M | 1.32 M | - | 747 K | 1.67 M | 760 K | - | 1.23 M | 877 K | 1.58 M | - | 1.62 M | 1.77 M | 1.58 M | - | 1.73 M | 2.01 M | 2.5 M | - | 1.4 M | 817 K | 2.06 M | - | 1.16 M | 610 K | 635 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.71 M | 610 K | 2.27 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Electromed
ELMD
|
64 M | $ 25.26 | -1.88 % | $ 214 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.0 | -3.85 % | $ 1.22 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 13.07 | -2.32 % | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.22 | -0.6 % | $ 49.6 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.3 | -0.15 % | $ 124 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.58 | -2.77 % | $ 459 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 167.78 | -8.25 % | $ 11.8 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.64 | 7.3 % | $ 39.8 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 10.3 | -7.04 % | $ 292 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Globus Medical
GMED
|
2.94 B | $ 88.32 | -2.67 % | $ 11.9 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.03 | -5.81 % | $ 5.63 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.82 | 5.13 % | $ 38.5 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 17.75 | -4.75 % | $ 1.21 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.89 | -5.33 % | $ 1.04 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 14.64 | -3.3 % | $ 343 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.17 | -3.6 % | $ 364 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | - | $ 17.6 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 35.4 | -3.78 % | $ 1.1 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 58.67 | -4.28 % | $ 3.2 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 52.88 | -4.05 % | $ 1.55 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.39 | 0.75 % | $ 64.5 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 83.0 | -1.94 % | $ 2.88 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.52 | -0.92 % | $ 47.7 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 22.3 | -5.39 % | $ 510 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 313.15 | -2.58 % | $ 120 B |